Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/1998

01-06-1998

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

Authors: Tomohiro Noda, Tomoyuki Watanabe, Akira Kohda, Shunji Hosokawa, Tadashi Suzuki

Published in: Investigational New Drugs | Issue 2/1998

Login to get access
Metadata
Title
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs
Authors
Tomohiro Noda
Tomoyuki Watanabe
Akira Kohda
Shunji Hosokawa
Tadashi Suzuki
Publication date
01-06-1998
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 2/1998
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1006088907271

Other articles of this Issue 2/1998

Investigational New Drugs 2/1998 Go to the issue

OriginalPaper

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial

OriginalPaper

Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma

OriginalPaper

Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia

OriginalPaper

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck

OriginalPaper

Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer

OriginalPaper

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits